BRPI0414864A - composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida - Google Patents
composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicidaInfo
- Publication number
- BRPI0414864A BRPI0414864A BRPI0414864-9A BRPI0414864A BRPI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- mycophenolic acid
- pharmaceutical composition
- rapamide
- mycophenolate sodium
- Prior art date
Links
- 229960000951 mycophenolic acid Drugs 0.000 title abstract 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title abstract 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0323202A GB0323202D0 (en) | 2003-10-03 | 2003-10-03 | Organic compounds |
| GB0323598A GB0323598D0 (en) | 2003-10-08 | 2003-10-08 | Organic compounds |
| GB0329852A GB0329852D0 (en) | 2003-12-23 | 2003-12-23 | Organic compounds |
| GB0405902A GB0405902D0 (en) | 2004-03-16 | 2004-03-16 | Organic compounds |
| GB0410714A GB0410714D0 (en) | 2004-05-13 | 2004-05-13 | Organic compounds |
| GB0419356A GB0419356D0 (en) | 2004-08-31 | 2004-08-31 | Organic compounds |
| PCT/EP2004/010998 WO2005034916A1 (en) | 2003-10-03 | 2004-10-01 | Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414864A true BRPI0414864A (pt) | 2006-11-28 |
Family
ID=34437795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414864-9A BRPI0414864A (pt) | 2003-10-03 | 2004-10-01 | composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070036857A1 (OSRAM) |
| EP (1) | EP1670437A1 (OSRAM) |
| JP (1) | JP2007507458A (OSRAM) |
| AR (1) | AR045957A1 (OSRAM) |
| AU (1) | AU2004280078B2 (OSRAM) |
| BR (1) | BRPI0414864A (OSRAM) |
| CA (1) | CA2538099A1 (OSRAM) |
| MX (1) | MXPA06003646A (OSRAM) |
| PE (1) | PE20050755A1 (OSRAM) |
| TW (1) | TW200520759A (OSRAM) |
| WO (1) | WO2005034916A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210787B2 (en) | 2002-02-01 | 2009-04-23 | Medinol Ltd. | Phosphorus-containing compounds & uses thereof |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2006086498A2 (en) * | 2005-02-08 | 2006-08-17 | Aspreva Pharmaceuticals Sa | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors |
| GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CA2640283A1 (en) * | 2006-02-13 | 2007-08-23 | Novartis Ag | High dosage of mycophenolic acid (mpa) |
| EP2094241A4 (en) * | 2006-11-14 | 2013-04-17 | Ariad Pharma Inc | ORAL FORMULATIONS |
| MX2010001711A (es) * | 2007-08-13 | 2010-03-11 | Panacea Biotec Ltd | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. |
| AU2009220779A1 (en) * | 2008-03-05 | 2009-09-11 | Panacea Biotec Limited | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
| AU2010264116B2 (en) * | 2009-06-25 | 2013-12-19 | Dupont Nutrition Biosciences Aps | Protein |
| WO2011046546A1 (en) * | 2009-10-13 | 2011-04-21 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| PH12014500746A1 (en) | 2011-10-06 | 2019-07-17 | Novartis Ag | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
| WO2014059309A1 (en) * | 2012-10-11 | 2014-04-17 | Theravida, Inc. | Pharmaceutical formulations of pilocarpine |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| WO2014167442A1 (en) * | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Pharmaceutical compositions comprising mycophenolic acid or salts thereof |
| CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| MA40982A (fr) | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| JP7385474B2 (ja) * | 2017-03-13 | 2023-11-22 | オカヴァ ファーマシューティカルズ， インコーポレイテッド | 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
| US20250282721A9 (en) * | 2021-12-23 | 2025-09-11 | Gencaps Sàrl | Drug delivery system comprising monomethyl fumarate |
| WO2023224914A1 (en) * | 2022-05-16 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Assessing and treating caveolinopathy diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2086642C (en) * | 1992-01-09 | 2004-06-15 | Randall E. Morris | Method of treating hyperproliferative vascular disease |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
| ES2248793T3 (es) * | 1993-10-01 | 2006-03-16 | Roche Palo Alto Llc | Suspensiones orales de alta dosis de mofetil micofenolato. |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| CN1233169A (zh) * | 1996-10-14 | 1999-10-27 | 弗·哈夫曼-拉罗切有限公司 | 一种粉末状制剂的制备工艺 |
| US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000067773A2 (en) * | 1999-05-10 | 2000-11-16 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
| US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| BR0306858A (pt) * | 2002-01-10 | 2004-11-03 | Novartis Ag | Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma |
| JP2006511475A (ja) * | 2002-09-18 | 2006-04-06 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 脈絡膜新生血管症の抑制方法 |
| CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| GB0301259D0 (en) * | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-30 AR ARP040103556A patent/AR045957A1/es unknown
- 2004-10-01 PE PE2004000963A patent/PE20050755A1/es not_active Application Discontinuation
- 2004-10-01 WO PCT/EP2004/010998 patent/WO2005034916A1/en not_active Ceased
- 2004-10-01 AU AU2004280078A patent/AU2004280078B2/en not_active Ceased
- 2004-10-01 CA CA002538099A patent/CA2538099A1/en not_active Abandoned
- 2004-10-01 JP JP2006530072A patent/JP2007507458A/ja active Pending
- 2004-10-01 EP EP04765757A patent/EP1670437A1/en not_active Withdrawn
- 2004-10-01 BR BRPI0414864-9A patent/BRPI0414864A/pt not_active IP Right Cessation
- 2004-10-01 US US10/570,752 patent/US20070036857A1/en not_active Abandoned
- 2004-10-01 MX MXPA06003646A patent/MXPA06003646A/es not_active Application Discontinuation
- 2004-10-01 TW TW093129854A patent/TW200520759A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06003646A (es) | 2006-06-05 |
| AU2004280078A1 (en) | 2005-04-21 |
| JP2007507458A (ja) | 2007-03-29 |
| US20070036857A1 (en) | 2007-02-15 |
| WO2005034916A1 (en) | 2005-04-21 |
| CA2538099A1 (en) | 2005-04-21 |
| TW200520759A (en) | 2005-07-01 |
| AR045957A1 (es) | 2005-11-16 |
| EP1670437A1 (en) | 2006-06-21 |
| PE20050755A1 (es) | 2005-11-28 |
| AU2004280078B2 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0414864A (pt) | composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida | |
| BR0206955A (pt) | Ligantes de receptores de canabinóides | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
| EP2269657A3 (en) | Prodrugs containing novel bio-cleavable linkers | |
| GT200200122A (es) | Imidazotriazinas | |
| EP2075011A3 (en) | Prodrugs containing bio-cleavable disulfide linkers | |
| BRPI0511504A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides | |
| BRPI0410418A (pt) | fenil quinolinas e seu uso como moduladores do receptor de estrogênio | |
| WO2006024479A3 (en) | Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin | |
| MA30152B1 (fr) | Suspension de fexofenadine | |
| DE602007011302D1 (de) | Ligustilid zur behandlung von erkrankungen des zentralen nervensystems | |
| BR0207640A (pt) | Composição farmacêutica oral de cefpodoxima proxetil | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
| EA200970124A1 (ru) | Производные 2-арилиндола в качестве ингибиторов npges-1 | |
| GT200100148A (es) | Derivados de 4-fenil-piridina. | |
| BR0315139A (pt) | Agentes antibacterianos de tetraidroquinolina tricìclica | |
| BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
| SE9901077D0 (sv) | Novel use | |
| BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
| BRPI0406824A (pt) | Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm | |
| DE602006020295D1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel | |
| BRPI0620229A8 (pt) | formulação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |